Expression of CD133 in differentiated thyroid cancer of young patients
Authors:
- Johnny DeladoëyJDJohnny Deladoëy
- Françoise Borson-ChazotFrançoise Borson-Chazot
- Rasha Abu-KhudirRARasha Abu-Khudir
- Alfredo FuscoAFAlfredo Fusco
- the group of Pathologists of the Rhône Alpes RegionTRthe group of Pathologists of the Rhône Alpes Region
- 13 March 2015
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 68 (6) , 434-440
Abstract
Aims: CD133 expression in cancer is frequently associated with poor outcome. Thyroid carcinomas are rare in childhood and adolescence and are associated with a higher risk of recurrence and more metastases than the adult tumours. The aim of the study was to assess whether the expression of CD133 in thyroid carcinomas of children, adolescents and young adults was correlated with clinical prognostic factors. Methods: Tissue microarrays were constructed with 235 tumours coming from 208 young adults with a median age of 28 years and 27 children with a median age of 13 years. An immunohistochemical study was performed with anti-CD133 antibody. CD133 expression was evaluated, using a semiquantitative score based on the percentage of positive cells. The mutation status of tumours was evaluated by reverse transcriptase PCR. Three cell lines were used to confirm CD133 expression by western blot. Results: CD133 expression was found in 43% of adult and 37% of child tumours and was confirmed by western blot in cell lines. In young adults, the expression of CD133 was significantly more frequent in patients with tumours >3 cm (p=0.04) and in patients with lymph node metastases (p=0.02). The expression of CD133 was more frequent in patients in whom the tumour presented a BRAF mutation (p=0.03). Conclusions: CD133 expression is correlated with tumour size, lymph nodes metastases and BRAF mutations in young adults. The presence of these cancer stem cells could offer new therapeutic alternatives for aggressive thyroid cancers.Keywords
This publication has 38 references indexed in Scilit:
- Phenotypic Characterization of Metastatic Anaplastic Thyroid Cancer Stem CellsPLOS ONE, 2013
- CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathwayHistopathology, 2012
- Oncogenic Alterations in Papillary Thyroid Cancers of Young PatientsThyroid®, 2012
- The Emerging Cell Biology of Thyroid Stem CellsThe Journal of Clinical Endocrinology & Metabolism, 2011
- Medullary Thyroid Carcinoma Cell Lines Contain a Self-Renewing CD133+Population that Is Dependent on Ret Proto-Oncogene ActivityThe Journal of Clinical Endocrinology & Metabolism, 2010
- CD133+ Anaplastic Thyroid Cancer Cells Initiate Tumors in Immunodeficient Mice and Are Regulated by ThyrotropinPLOS ONE, 2009
- In Vitro Identification and Characterization of CD133pos Cancer Stem-Like Cells in Anaplastic Thyroid Carcinoma Cell LinesPLOS ONE, 2008
- Thyroid stem cells: lessons from normal development and thyroid cancerEndocrine-Related Cancer, 2008
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- BRAF Mutations are Uncommon in Papillary Thyroid Cancer of Young PatientsThyroid®, 2005